The EU-funded Innovative Training Network THERADNET aims to provide a multidisciplinary and intersectorial training to 15 early stage researchers (ESRs) in the field of experimental radiation oncology. THERADNET stands for: "International NETwork for training and innovations in THErapeutic RADiation".
As a consortium of eight leading Radiobiology Laboratories in Europe, THERADNET will bring together radiation biologists, clinician scientists, clinicians and non-academic partners across Europe to investigate the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. The research program covers three scientific work packages addressing tumor sensitization, normal tissue protection and adaptation and escape mechanisms.
Metabolic control of radioresistance in breast cancer
Host: Université catholique de Louvain (UCLouvain)
Contact person: firstname.lastname@example.org.
Location: Brussels, Belgium
Breast cancer is the first type of cancer in women worldwide, and Europe has the highest rate of diagnosis. Chemoradiotherapy associated with surgery is part of standard breast cancer clinical care, but tumors can relapse, often because cancer cells acquire intrinsic chemoradioresistance. Our project aims to test the possibility that metabolic alterations are responsible for the acquired radioresistance of breast cancer cells to X-rays. Based on previous observations of our team in head and neck squamous cell carcinoma cells the focus will be set on mitochondria, as these organelles control DNA repair (ATP generation), cell proliferation (biosynthesis) and apoptosis (cytochrome c, superoxide and Ca2+ release). Because it is not protected by histones and has limited repair capacities, mitochondrial DNA (mtDNA) also potentially constitutes a main target of radiotherapy, which will be investigated together with mitochondrial turnover (mitophagy and mitochondrial biogenesis).
This project will identify a metabolic profile associated with radioresistance and lay the ground for antimetabolic strategies aimed to radiosensitize breast cancer cells and, potentially, other cancer types.
Applicant should send in a single PDF file (1) the annexed application form, (2) a motivation letter, (3) a complete CV with bibliography and (4) contact details of 3 supporting scientists to Prof. Pierre Sonveaux (email@example.com).
- You will be employed by the host organisation for 20 months. Extended duration of a PhD-project will be possible
- You will benefit from the designed training program offered by the host organisation and the consortium.
- You will participate in international secondments to other organisations within the THERADNET network and in outreach activities targeted at a wide audience.
- You will embark on secondments to THERADNET partners for trans- and interdisciplinary research.
- You will be part of an international research consortium of over > 25 researchers
- You will get in contact with the other members of this international consortium and will benefit from the joint training platform to develop skills in the area of applied radiation biology, translational oncology research and personalized medicine.
Applications will be evaluated objectively. Top 3 candidates will be interviewed.
REQUIRED EDUCATION LEVEL
Biological sciences: Master Degree or equivalent
Pharmacological sciences: Master Degree or equivalent
Medical sciences: Master Degree or equivalent
- Holder of a graduation degree/Master in Medical, Pharmaceutical or Biomedical Sciences or related.
- Excellent grades and/or class rankings.
- Excellent theoretical knowledge of biochemistry.
- Good theoretical knowledge of radiation therapy.
- Willingness to work with in vivo cancer models.
- High level of motivation.
- Previous work in a laboratory environment will be a plus.
- Fluid in spoken and written English.
- Applicants must fulfill the “H2020 MSCA Mobility Rule” and the “H2020 MSCA eligibility criteria”
- Applicants can be of any nationality.
- Applicants must be eligible to enrol on a PhD program at the host institution (or at a designated university in case the host institution is a non-academic organisation).
- Applicants must have an ability to understand and express themselves in both written and spoken English to a level that is sufficiently high for them to derive the full benefit from the network training.